News
Merck wins FDA nod for Keytruda as adjuvant kidney cancer tr...
Merck & Co has chalked up another win in drive to move PD-1 inhibitor Keytruda earlier in the treatment pathway for cancer, after the FDA greenlit use of the drug as post-surgery (adjuv
